Ally Bridge Group (NY) LLC
Long book
$100.7M
Q1 2026
Positions
21
Top-10 weight
65%
concentration
Last quarter
+16.7%
SPY +14.8%
Turnover
52%
of book per quarter
Strategy in plain words
auto-generated from filingsAlly Bridge Group (NY) LLC is a concentrated fundamental stock-picker, specialised in healthcare (100% of the long book), running a $100.7M US long book across 21 positions.
The portfolio is concentrated: the top 10 names carry 65% of the portfolio. Turnover is high — positions rotate quickly, so individual names matter less than the process. Current anchor positions: PRAXIS PRECISION MEDICINES I, MINERVA NEUROSCIENCES INC, SOLENO THERAPEUTICS INC, OVID THERAPEUTICS INC, COMPASS PATHWAYS PLC.
Over the last 9 quarters its long book ran on average 0pp per quarter ahead of the S&P 500, beating the index in 4 of 9 quarters. We rate its filings as signal-bearing: position changes reflect genuine views.
Implied long-book return vs S&P 500
methodology: positions priced quarterly, no shorts/options Fund long book S&P 500
Q1 2024
-5.6%
Q2 2024
+3.4%
Q3 2024
-8.0%
Q4 2024
-17.3%
Q1 2025
-2.9%
Q2 2025
+34.1%
Q3 2025
+7.1%
Q4 2025
+13.3%
Q1 2026
+16.7%
Sector allocation
Healthcare 92%
Other 8%
Long book by quarter
What does Ally Bridge own?
Q1 2026 13F| Company | Sector | Shares | Value | % of book | Change |
|---|---|---|---|---|---|
| PRAX PRAXIS PRECISION MEDICINES I | Healthcare | 32.8K | $10.6M | 10.5% | +65.0% |
| NERV MINERVA NEUROSCIENCES INC | Healthcare | 1.7M | $10.0M | 9.9% | Held |
| SLNOEUR SOLENO THERAPEUTICS INC | — | 200.0K | $6.7M | 6.7% | +19.0% |
| OVID OVID THERAPEUTICS INC | Healthcare | 2.8M | $6.3M | 6.2% | +57.9% |
| TARS TARSUS PHARMACEUTICALS INC | Healthcare | 80.9K | $5.7M | 5.6% | New |
| SLDB SOLID BIOSCIENCES INC | Healthcare | 767.0K | $5.5M | 5.5% | +85.4% |
| PMN PROMIS NEUROSCIENCES INC | Healthcare | 414.2K | $5.3M | 5.2% | +66.1% |
| EWTX EDGEWISE THERAPEUTICS INC | Healthcare | 161.0K | $5.1M | 5.0% | -17.4% |
| EPRX EUPRAXIA PHARMACEUTICALS INC | Healthcare | 660.4K | $4.8M | 4.7% | +66.0% |
| CTMX CYTOMX THERAPEUTICS INC | Healthcare | 900.0K | $4.2M | 4.2% | New |
| CATX PERSPECTIVE THERAPEUTICS INC | Healthcare | 926.6K | $3.9M | 3.8% | New |
| ALMS ALUMIS INC | Healthcare | 167.0K | $3.7M | 3.7% | New |
| URGN UROGEN PHARMA LTD | Healthcare | 202.1K | $3.6M | 3.6% | New |
| CAPR CAPRICOR THERAPEUTICS INC | Healthcare | 113.9K | $3.5M | 3.4% | New |
| WHWK WHITEHAWK THERAPEUTICS INC | Healthcare | 817.9K | $2.8M | 2.8% | Held |
| IKT INHIBIKASE THERAPEUTICS INC | Healthcare | 1.3M | $2.2M | 2.2% | New |
| ANTX AN2 THERAPEUTICS INC | Healthcare | 526.3K | $1.8M | 1.8% | New |
| RLMD RELMADA THERAPEUTICS INC | Healthcare | 210.5K | $1.5M | 1.5% | New |
13F filing history
| Period | Form | Filed | Entries | Reported value | Flags | Source |
|---|---|---|---|---|---|---|
| Q1 2026 | 13F-HR | May 18, 2026 | 28 | $123.8M | canonical | SEC ↗ |
| Q4 2025 | 13F-HR | Feb 17, 2026 | 20 | $96.0M | canonical | SEC ↗ |
| Q3 2025 | 13F-HR | Nov 14, 2025 | 25 | $164.2M | canonical | SEC ↗ |
| Q2 2025 | 13F-HR | Aug 14, 2025 | 24 | $120.2M | canonical | SEC ↗ |
| Q1 2025 | 13F-HR | May 15, 2025 | 28 | $110.9M | canonical | SEC ↗ |
| Q4 2024 | 13F-HR | Feb 14, 2025 | 30 | $116.6M | canonical | SEC ↗ |
| Q3 2024 | 13F-HR | Nov 14, 2024 | 29 | $186.8M | canonical | SEC ↗ |
| Q2 2024 | 13F-HR | Aug 14, 2024 | 25 | $167.9M | canonical | SEC ↗ |
| Q1 2024 | 13F-HR | May 15, 2024 | 22 | $179.9M | canonical | SEC ↗ |